China-based Alioth Biotech (Shanghai) Co., Ltd has raised close to RMB 100 million (USD 13.9 million) in a Series A financing round. The round was led by Matrix Partners and Legend Capital, with participation from Shanghai Yishuishan Enterprise Consulting Partnership Limited. The proceeds will be used to construct a membrane material research and development (R&D) center, develop pharmaceutical process filter product facilities, and scale up the talent team.
Company Background and Focus
Founded in 2021, Alioth Biotech is focused on the development and manufacturing of filtration-technology-centered pharma processing products. The company has established GMP-compliant manufacturing bases in Shanghai and Hangzhou, highlighting its commitment to quality and regulatory compliance.
Future Outlook
The Series A financing underscores Alioth Biotech’s strategic focus on advancing filtration technology in the pharmaceutical industry. By investing in R&D and expanding its manufacturing capabilities, Alioth aims to enhance its product offerings and strengthen its market position in the filtration technology sector.-Fineline Info & Tech
